Quinoxaline 1,4-dioxide: A viable option for the development of antitubercular drugs

Abstract

Tuberculosis is a major infectious disease in the world, which causes high mortality. The treatment consists of drugs of first and second line; however, its effectiveness is limited by several factors, mainly the presence of resistant and/or multi-drug resistant strains. This work reviews compounds derived from quinoxaline 1, 4-dioxide with antimycobacterial activity in in vitro and in vivo models as an option for the development of new drugs against tuberculosis.